Evidence map›Paper›PMID 30885149›Full record

ArticleBMC cancer2019

Increased MET gene copy number negatively affects the survival of esophageal squamous cell carcinoma patients.

Yanqiu Wang, Zhengzeng Jiang, Chen Xu, Hao Wang, Lijie Tan, Jieakesu Su, Xin Wang, Dongxian Jiang, Yingyong Hou, Qi Song

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. MET overexpression and intratumor heterogeneity in esophageal squamous cell carcinoma.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yanqiu WangDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China.
Zhengzeng JiangDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China.
Chen XuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China.
Hao WangDepartment of Thoracic surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China.
Lijie TanDepartment of Thoracic surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China.
Jieakesu SuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China.
Xin WangDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China.
Dongxian JiangDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China.
Yingyong HouDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China. houyingyong@aliyun.com.
Qi SongDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China. qisong725@gmail.com.

Funding

Foundation of Shanghai Municipal Commission of Health and Family Planning (CN) 2015ZB0201National Natural Science Foundation of China 81702372Natural Science Foundation of Shanghai (CN) 18ZR1406800
6 · The paper itself

Abstract

backgroundsSince Mesenchymal epithelial transition (MET) amplification has been regarded as a potential treatment target, the knowledge of its prevalence and prognostic importance is crucial. However, its clinical pathologic characteristics are not well known in esophageal squamous cell carcinoma (ESCC).

methodsWe investigated MET gene status with fluorescence in situ hybridization (FISH) assay in 495 ESCC cases using tissue microarrays. Prognostic significance as well as correlations with various clinicopathological parameters was evaluated.

resultsAmong 495 patients, 28 (5.7%) cases were MET FISH positive, including 5 cases (1%) with true gene amplification. There were no statistically significant associations between MET FISH-positivity and clinicopathologic characteristics. A significantly poorer prognosis was observed in 28 patients with MET FISH-positivity (disease free survival/DFS, P < 0.001 and overall survival/OS, P = 0.001). Multivariate analysis revealed MET FISH-positivity was an independent prognostic factor for DFS (hazard ratio/HR, 1.953; 95% confidence interval/CI, 1.271-2.999; P = 0.002) and OS (HR, 1.926; 95% CI, 1.243-2.983; P = 0.003). MET FISH-positivity was associated with DFS (P = 0.022 and 0.020) and OS (P = 0.046 and 0.024) both in stage I-II ESCC and in stage III-IVa ESCC. No statistical significance (DFS, P = 0.492 and OS, P = 0.344) was detected between stage I-II ESCC with MET FISH-positivity and stage III-IVa ESCC with FISH-negativity.

conclusionsIncreased MET gene copy number is an independent prognostic factor in ESCC, and ESCC might have potentially been up-staged by increased MET gene copy number. The results indicate that increased MET gene copy number is a very promising parameter, in clinical therapy and follow-up plans.

Indexed as

Gene AmplificationAdultAgedAged, 80 and overBiomarkers, TumorDisease-Free SurvivalEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaEsophagusFemaleGene DosageHumansIn Situ Hybridization, FluorescenceMaleMiddle AgedNeoplasm StagingBiomarkers, TumorMET protein, humanProto-Oncogene Proteins c-metClinical stageEsophageal squamous cell carcinoma (ESCC)Fluorescence in situ hybridization (FISH)Increased MET gene copy numberPrognosis

Identifiers

PMID30885149
PMCPMC6421677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.